Where is Lunit headquartered?

Lunit is headquartered in Seoul, South Korea. The company has a team of 293 people.

Lunit operates in the AI in Healthcare sector. Lunit develops AI-powered medical imaging solutions for cancer detection and precision oncology, enhancing diagnostic accuracy and efficiency Improves diagnostic accuracy, reduces human error, and streamlines workflows through advanced AI analytics for medical imaging with FDA-cleared solutions

When was Lunit founded?

Lunit was founded in 2013. It is based in Seoul, South Korea.

Who is the CEO of Lunit?

Beomseok Brandon Suh is the CEO of Lunit. The company was founded in 2013.

Where is Lunit located?

Lunit is headquartered in Seoul, South Korea.

What funding stage is Lunit at?

Lunit is currently at the Public stage.

How many employees does Lunit have?

Lunit has approximately 293 employees.

Lunit

Category: AI in Healthcare

Lunit develops AI-powered medical imaging solutions for cancer detection and precision oncology, enhancing diagnostic accuracy and efficiency Lunit was founded in 2013. The company is led by Beomseok Brandon Suh. Based in Seoul, South Korea. Team size: 293. Total funding raised: $285M+. Latest round: Public company (KOSDAQ: 328130) with $150M capital increase completed in November 2023. Key investors include SoftBank Ventures, Mirae Asset Venture Investment, Naver D2SF, Kolon Investment, Microsoft, HealthQuest Capital, Casdin Capital, American Cancer Society BrightEdge, Tybourne Capital, Legend Capital.

Founded: 2013
Headquarters: Seoul, South Korea
Team size: 293
Total funding: $285M+

Value proposition

Improves diagnostic accuracy, reduces human error, and streamlines workflows through advanced AI analytics for medical imaging with FDA-cleared solutions

Products and solutions

Lunit INSIGHT MMG (2D mammography analysis), Lunit INSIGHT DBT (3D breast imaging analysis), Lunit INSIGHT CXR (chest X-ray analysis), Lunit INSIGHT Risk (mammography-based breast cancer risk prediction), Lunit SCOPE IO (tumor-immune landscape analysis), Lunit SCOPE IHC Suite (IHC quantification), Lunit SCOPE GP (genotype prediction), Volpara Scorecard (density assessment), Volpara Risk Pathways (risk assessment), Volpara Analytics (quality management)

Unique value

Specializes in deep learning algorithms for medical imaging with FDA-cleared AI solutions, integrated clinical workflows, and partnerships with leading medical imaging OEM systems (GE, Philips, Fujifilm). Unique combination of cancer screening and precision oncology AI platforms

Target customer

Healthcare institutions, radiologists, oncologists, and medical professionals focusing on cancer screening and diagnosis

Industries served

Radiology, Oncology, Medical Imaging, Precision Medicine, Healthcare Technology

Technology advantage

Proprietary AI models trained on extensive global medical datasets, combined with strategic partnerships for seamless integration into existing healthcare workflows. Over 85 patents and FDA clearances for multiple products

How they differentiate

Lunit differentiates through its FDA-cleared AI solutions, integrated clinical workflows, comprehensive breast cancer ecosystem, and partnerships with leading healthcare institutions. Their focus on precision medicine and biomarker analysis, combined with AI-driven risk prediction systems like Lunit INSIGHT Risk, enhances diagnostic consistency and patient outcomes

Main competitors

Aidoc, PathAI, Zebra Medical Vision, GE Healthcare, Philips Healthcare, Fujifilm Medical Systems, Hologic, iCAD

Key partnerships

GE Healthcare, Philips, Samsung Electronics, Fujifilm, Microsoft, SimonMed Imaging Partners, Guardant Health, Volpara Health (acquired 2023), CARPL.ai, Starvision Service GmbH (Germany), National Cancer Institute, NHS Trust

Notable customers

GE Healthcare, Microsoft, National Cancer Institute, NHS Trust, Guardant Health, SimonMed Imaging Partners, Bumrungrad International Hospital, Akumin (US diagnostic imaging network)

Major milestones

FDA clearance for Lunit INSIGHT MMG (breast cancer detection, 2021), KOSDAQ IPO (July 2022), Partnership with Microsoft to scale AI diagnostic tools (2025), Acquisition of Volpara Health Technologies (2023), Submission of FDA 510(k) for Lunit INSIGHT Risk (December 2025), $150M capital increase completed (November 2023), 10,000+ customer sites globally (2025), Supply agreement with Akumin for US expansion (2025)

Growth metrics

Revenue: KRW 37.1 billion (H1 2025, 113.5% YoY growth); 293 employees; 10,000+ healthcare institutions served globally; 65+ countries; Operating loss ratio improved by 76 percentage points YoY

Market positioning

Lunit positions itself as a global leader in AI-powered cancer diagnostics, targeting both early detection and treatment guidance. Their solutions are deployed in over 10,000 institutions across 65+ countries, with a strong emphasis on global expansion and precision oncology

Geographic focus

Primarily focused on Asia (home market in South Korea), North America (U.S. partnerships with GE, Philips, and Microsoft), and Europe (collaborations with NHS Trust, French UniHA tender, Italian national programs, and German healthcare providers)

Patents and IP

85+ patents as of 2025, with continuous innovation in AI-powered medical imaging and cancer detection

About Beomseok Brandon Suh

Medical doctor with degrees from Seoul National University College of Medicine (M.D., M.B.A., M.P.H.), board certified in Family Medicine, former Chief Medical Officer at Lunit (2016-2019), joined Lunit in 2016 as CMO before becoming CEO

Official website: https://www.lunit.io/